Nevro Corp. (NYSE:NVRO)‘s stock had its “buy” rating reiterated by research analysts at B. Riley in a research note issued to investors on Friday.

Several other equities analysts have also weighed in on NVRO. Piper Jaffray Cos. began coverage on shares of Nevro Corp. in a research report on Friday, July 22nd. They set an “overweight” rating for the company. Wells Fargo & Co. began coverage on shares of Nevro Corp. in a research report on Tuesday, July 12th. They set an “outperform” rating for the company. William Blair restated an “outperform” rating on shares of Nevro Corp. in a research report on Monday, July 18th. Finally, Bank of America Corp. began coverage on shares of Nevro Corp. in a research report on Monday, August 8th. They set a “buy” rating for the company. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $76.75.

Nevro Corp. (NYSE:NVRO) traded down 0.49% during trading on Friday, reaching $95.48. 114,817 shares of the company were exchanged. The company’s market capitalization is $2.72 billion. The firm’s 50-day moving average is $93.56 and its 200 day moving average is $74.38. Nevro Corp. has a one year low of $36.51 and a one year high of $100.83.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/b-riley-reiterates-buy-rating-for-nevro-corp-nvro.html

Several institutional investors have recently added to or reduced their stakes in the stock. Springbok Capital Management LLC raised its position in Nevro Corp. by 303.8% in the first quarter. Springbok Capital Management LLC now owns 2,685 shares of the company’s stock worth $151,000 after buying an additional 2,020 shares during the period. JPMorgan Chase & Co. raised its position in Nevro Corp. by 1.4% in the first quarter. JPMorgan Chase & Co. now owns 852,758 shares of the company’s stock worth $47,976,000 after buying an additional 11,695 shares during the period. Cormorant Asset Management LLC raised its position in Nevro Corp. by 82.9% in the first quarter. Cormorant Asset Management LLC now owns 485,386 shares of the company’s stock worth $27,308,000 after buying an additional 220,000 shares during the period. UBS Asset Management Americas Inc. raised its position in Nevro Corp. by 31.5% in the first quarter. UBS Asset Management Americas Inc. now owns 7,100 shares of the company’s stock worth $399,000 after buying an additional 1,700 shares during the period. Finally, Geode Capital Management LLC raised its position in Nevro Corp. by 2.2% in the first quarter. Geode Capital Management LLC now owns 89,667 shares of the company’s stock worth $5,044,000 after buying an additional 1,907 shares during the period.

About Nevro Corp.

Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.

5 Day Chart for NYSE:NVRO

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.